{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:29:23Z","timestamp":1792441763360,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI132994"],"award-info":[{"award-number":["R21AI132994"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI136979"],"award-info":[{"award-number":["R01AI136979"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SINGH24R0"],"award-info":[{"award-number":["SINGH24R0"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dalbavancin exposures select for VAN and daptomycin cross-resistance in Staphylococcus aureus often by walK-related mutations. Oritavancin is another long-acting lipoglycopeptide, but its proclivity to select for cross-resistance is unknown. The objective of this study was to determine if post-distributional pharmacokinetic oritavancin exposures select for meaningful susceptibility changes in S. aureus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We simulated average post-distributional, free-drug exposures of oritavancin 1200\u2005mg IV once (fCmax 11.2\u2005\u00b5g\/mL; \u03b2-elimination t1\/2 13.4\u2005h; \u03b3-elimination t1\/2 245\u2005h) in an in vitro pharmacodynamic model for 28 days against five S. aureus including four MRSA. Samples were taken daily for colony enumeration and resistance screening. Susceptibility testing was repeated on isolates from resistance screening plates against oritavancin, vancomycin, daptomycin, dalbavancin and 6 beta-lactams with varying penicillin-binding protein affinities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Tested oritavancin exposures were bactericidal against 5\/5 strains for 2\u201317\u2005days before regrowth of less-susceptible subpopulations occurred. Isolates with reduced susceptibility to oritavancin were detected as early as 5 days, but the MIC increased above the susceptibility breakpoint (&amp;gt;0.125\u2005mg\/L) in 4\/5 strains eventually. Vancomycin and daptomycin MICs increased by 2- to 8-fold but did not exceed the susceptibility breakpoints in most isolates. \u03b2-lactam MICs were largely unchanged among the recovered isolates with reduced oritavancin susceptibility. Mutations were diverse but often involved purR with 13 unique variants identified among 4\/5 strains.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Oritavancin-selected resistance was primarily associated with purR mutation and less frequently associated with cross-resistance and walK mutation than dalbavancin-selected resistance in similar strains and conditions. The reason for this is unclear but may stem from differences in the mechanism(s) and divergent mutational pathways.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf042","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:35:24Z","timestamp":1738269324000},"page":"1108-1115","source":"Crossref","is-referenced-by-count":4,"title":["Simulated exposures of oritavancin in <i>in vitro<\/i> pharmacodynamic models select for methicillin-resistant <i>Staphylococcus aureus<\/i> with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-4098","authenticated-orcid":false,"given":"Brian J","family":"Werth","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, University of Washington , 1959 NE Pacific St., HSB H-375, Box 357630, Seattle, WA 98195-7630 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael A","family":"Barreras Beltran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, University of Washington , 1959 NE Pacific St., HSB H-375, Box 357630, Seattle, WA 98195-7630 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsi","family":"Penewit","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, School of Pharmacy, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Waalkes","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, School of Pharmacy, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, School of Pharmacy, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Salipante","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, School of Pharmacy, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-5200","authenticated-orcid":false,"given":"Libin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2025040208391465800_dkaf042-B1","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025040208391465800_dkaf042-B2","doi-asserted-by":"publisher","first-page":"688357","DOI":"10.3389\/fmolb.2021.688357","article-title":"Synergy between beta-lactams and lipo-, glyco-, and lipoglycopeptides, is independent of the seesaw effect in methicillin-resistant Staphylococcus aureus","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2025040208391465800_dkaf042-B3","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cid\/ciac341","article-title":"Emergence of dalbavancin, vancomycin, and daptomycin non-susceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization","volume":"75","author":"Zhang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025040208391465800_dkaf042-B4","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","article-title":"Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus","volume":"27","author":"Werth","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2025040208391465800_dkaf042-B5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-3164.2009.00856.x","article-title":"New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach","volume":"20","author":"Blondeau","year":"2009","journal-title":"Vet Dermatol"},{"key":"2025040208391465800_dkaf042-B6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated","volume":"44","author":"Drlica","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025040208391465800_dkaf042-B7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"2025040208391465800_dkaf042-B8","doi-asserted-by":"publisher","first-page":"e1002359","DOI":"10.1371\/journal.ppat.1002359","article-title":"Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR","volume":"7","author":"Howden","year":"2011","journal-title":"PLoS Pathog"},{"key":"2025040208391465800_dkaf042-B9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ijantimicag.2011.06.010","article-title":"Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus","volume":"38","author":"Patel","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2025040208391465800_dkaf042-B10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/antibiotics12050928","article-title":"Adaptive laboratory evolution of Staphylococcus aureus resistance to vancomycin and daptomycin: mutation patterns and cross-resistance","volume":"12","author":"Gostev","year":"2023","journal-title":"Antibiotics"},{"key":"2025040208391465800_dkaf042-B11","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025040208391465800_dkaf042-B12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.diagmicrobio.2017.06.023","article-title":"In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci","volume":"89","author":"Arhin","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025040208391465800_dkaf042-B13","doi-asserted-by":"publisher","first-page":"e0261420","DOI":"10.1128\/aac.02614-20","article-title":"New perspectives on antimicrobial agents: long-acting lipoglycopeptides","volume":"66","author":"Tran","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmacy10010001","article-title":"Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care","volume":"10","author":"Antosz","year":"2021","journal-title":"Pharmacy"},{"key":"2025040208391465800_dkaf042-B15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/idr14020032","article-title":"Evaluating the use of dalbavancin for off-label indications","volume":"14","author":"Taylor","year":"2022","journal-title":"Infect Dis Rep"},{"key":"2025040208391465800_dkaf042-B16","doi-asserted-by":"publisher","first-page":"ofac335","DOI":"10.1093\/ofid\/ofac335","article-title":"Comparison of sequential dalbavancin with standard-of-care treatment for Staphylococcus aureus bloodstream infections","volume":"9","author":"Molina","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025040208391465800_dkaf042-B17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1172\/JCI111965","article-title":"Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin","volume":"76","author":"Chambers","year":"1985","journal-title":"J Clin Invest"},{"key":"2025040208391465800_dkaf042-B18","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1128\/AAC.00594-13","article-title":"beta-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus","volume":"57","author":"Berti","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B19","volume-title":"Rocephin (Ceftriaxone for Injection USP) Package Insert","author":"Genentech USA, Inc","year":"2010"},{"key":"2025040208391465800_dkaf042-B20","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1128\/AAC.29.2.333","article-title":"Possible physiological functions of penicillin-binding proteins in Staphylococcus aureus","volume":"29","author":"Georgopapadakou","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1128\/AAC.14.6.866","article-title":"Use of cefoxitin, new cephalosporin-like antibiotic, in the treatment of aerobic and anaerobic infections","volume":"14","author":"Nair","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B23","volume-title":"M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for bacteria That Grow Aerobically; Approved Standard- Tenth Edition","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"2025040208391465800_dkaf042-B24","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1128\/AAC.00687-16","article-title":"Fosfomycin enhances the activity of daptomycin against vancomycin-resistant enterococci in an in vitro pharmacokinetic-pharmacodynamic model","volume":"60","author":"Hall Snyder","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B26","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1128\/AAC.00176-15","article-title":"Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials","volume":"59","author":"Rubino","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1128\/AAC.01428-12","article-title":"Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic\/pharmacodynamic model of methicillin-resistant Staphylococcus Aureus infection","volume":"57","author":"Belley","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B28","doi-asserted-by":"publisher","first-page":"e1005413","DOI":"10.1371\/journal.pgen.1005413","article-title":"A year of infection in the intensive care unit: prospective whole genome sequencing of bacterial clinical isolates reveals cryptic transmissions and novel Microbiota","volume":"11","author":"Roach","year":"2015","journal-title":"PLoS Genet"},{"key":"2025040208391465800_dkaf042-B29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1101\/gr.214346.116","article-title":"ABySS 2.0: resource-efficient assembly of large genomes using a Bloom filter","volume":"27","author":"Jackman","year":"2017","journal-title":"Genome Res"},{"key":"2025040208391465800_dkaf042-B30","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2025040208391465800_dkaf042-B31","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2025040208391465800_dkaf042-B32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"2025040208391465800_dkaf042-B33","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","article-title":"Variant review with the integrative genomics viewer","volume":"77","author":"Robinson","year":"2017","journal-title":"Cancer Res"},{"key":"2025040208391465800_dkaf042-B34","author":"The European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025040208391465800_dkaf042-B35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-World experience with oritavancin therapy in invasive gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2025040208391465800_dkaf042-B36","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1128\/AAC.01060-06","article-title":"Lack of relationship between purine biosynthesis and vancomycin resistance in Staphylococcus aureus: a cautionary tale for microarray interpretation","volume":"51","author":"Fox","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208391465800_dkaf042-B37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aay3041","article-title":"Effect of tolerance on the evolution of antibiotic resistance under drug combinations","volume":"367","author":"Liu","year":"2020","journal-title":"Science"},{"key":"2025040208391465800_dkaf042-B38","doi-asserted-by":"publisher","first-page":"589468","DOI":"10.3389\/fdgth.2021.583468","article-title":"Digital insights into nucleotide metabolism and antibiotic treatment failure","volume":"3","author":"Lopatkin","year":"2021","journal-title":"Front Digit Health"},{"key":"2025040208391465800_dkaf042-B39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41467-019-08724-x","article-title":"Stress-induced inactivation of the Staphylococcus aureus purine biosynthesis repressor leads to hypervirulence","volume":"10","author":"Goncheva","year":"2019","journal-title":"Nat Commun"},{"key":"2025040208391465800_dkaf042-B40","doi-asserted-by":"publisher","first-page":"13563","DOI":"10.1073\/pnas.1904280116","article-title":"The purine biosynthesis regulator PurR moonlights as a virulence regulator in Staphylococcus aureus","volume":"116","author":"Sause","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040208391465800_dkaf042-B41","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/infdis\/jiad577","article-title":"The purine biosynthesis repressor, PurR, contributes to vancomycin susceptibility of methicillin-resistant Staphylococcus aureus in experimental endocarditis","volume":"229","author":"Xiong","year":"2024","journal-title":"J Infect Dis"},{"key":"2025040208391465800_dkaf042-B42","doi-asserted-by":"publisher","first-page":"a010306","DOI":"10.1101\/cshperspect.a010306","article-title":"Bacterial biofilms: development, dispersal, and therapeutic strategies in the Dawn of the postantibiotic era","volume":"3","author":"Kostakioti","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025040208391465800_dkaf042-B43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jmsacl.2023.12.003","article-title":"Therapeutic drug monitoring of glycopeptide antimicrobials: an overview of liquid chromatography-tandem mass spectrometry methods","volume":"31","author":"Cafaro","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/1108\/61857622\/dkaf042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/1108\/61857622\/dkaf042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T09:29:26Z","timestamp":1743586166000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/4\/1108\/8010197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,12]]},"published-print":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf042","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,12]]}}}